Prescient

Prescient Therapeutics is a clinical-stage oncology company developing novel, personalized therapies for a range of cancers. The company's portfolio includes two main pillars: a pipeline of clinical-stage small molecule inhibitors targeting key survival pathways and the OmniCAR modular CAR-T platform. OmniCAR aims to overcome the limitations of current CAR-T therapies by providing a "plug-and-play" system that allows for multi-antigen targeting and controllable activity. Additionally, the company is advancing CellPryme, a platform designed to enhance the performance of adoptive cell therapies. Prescient is headquartered in Melbourne, Australia, and is listed on the Australian Securities Exchange.